Nfocus Neuromedical, Inc. Luna(TM) Aneurysm Embolization System Receives CE Mark

Significant milestone for innovative device designed to treat brain aneurysms -

PALO ALTO, California, February 15, 2011 - Nfocus Neuromedical, Inc., an innovative medical device company with a
focus on the next generation treatment for brain aneurysms, announced today
that its Luna(TM) Aneurysm Embolization System (AES) received CE Mark for the
treatment of patients with brain aneurysms. The Luna AES is designed to be a
single-deployment, easy-to-use system for the treatment of brain aneurysms
both pre- and post-rupture.

"Brain aneurysm treatment historically has been the domain of either
surgery or, more recently, catheter-placed wire coils," said Eric Milledge,
CEO, Nfocus Neuromedical. "Surgery can be traumatic and expensive, and coils
may fail to fully treat an aneurysm. The Luna AES represents a dramatic step
forward in the treatment of these patients."

It is estimated that up to one in 15 people will develop a brain aneurysm
during their lifetime.(1) Rupture of an aneurysm can cause stroke, brain
damage and even death.

The Luna AES treats brain aneurysms by blocking (embolizing) blood flow
while providing a scaffold to encourage tissue growth across an aneurysm
opening and create a plug. The Luna uses a self-expandable, multi-layer oval
implant made from Nitinol, a nickel-titanium alloy. The properties of the
device allow it to easily compress within a conventional catheter, and then
rapidly and easily open to full size once deployed within an aneurysm.

"CE Mark approval is an important milestone for Nfocus," said Robert
O'Holla, vice president of regulatory affairs, Nfocus Neuromedical. "The Luna
AES is our flagship product and we look forward to working with physicians
and hospitals in Europe to advance this important new technology."

About Nfocus Neuromedical, Inc.

Nfocus is developing the next generation treatment for brain aneurysms.
The company's innovative LUNA(TM) product is a single-deployment, easy-to-use
embolization device designed to be a direct replacement to detachable coils.
Nfocus is backed by three major U.S.- and OUS-based venture funds: DFJ
ePlanet Capital, Technology Partners, and InCube Ventures. Other investors
include Raffles Capital and Endeavor Vision. More information can be found at
www.nfocusneuro.com.

(1) - www.brainaneurysm.com/

Martin Dieck, President and COO of Nfocus Neuromedical, +1-650-845-3041